The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Still River Systems Inc. change its name to Mevion Medical Systems Inc. ahead of its push to get its proton therapy device, the Mevion S250, to market.
The Littleton, Mass.-based firm’s move marks its shift from a research & development company to a commercial manufacturer, according to a press release.
Proton therapy delivers therapeutic doses of radiation to tumors. Because the systems are so large and expensive it’s not widely available, a situation Mevion aims to change.
Personalized medicine test maker AssureRx Health completed an $11 million Series B round.
The Mason, Ohio-based company plans to use the funding to expand sales and marketing for its GeneSightRx test, which helps doctors pick the right psychiatric drugs for patients based on their genes. The company launched the test in 2009.
AssureRx also intends use the investment to develop an unspecified second product, according to the company.
The Mass. Institute of Technology sued Still River Systems Inc. over infringement of three of its patents and unpaid licensing fees.
The school filed a complaint Dec. 23 in the U.S. District Court for Massachusetts alleging that the Littleton, Mass.-based company built technology intended for proton-based radiotherapy applications that relies on its patents. Still River also failed to pay fees for a licensing agreement it entered with MIT, the school alleges.
The Mass. Institute of Technology is suing Still River Systems Inc. for rights to the company’s technology.
The school filed a complaint Dec. 17 in the U.S. District Court for Massachusetts alleging that the Littleton, Mass.-based radiation-therapy developer incorrectly left an MIT researcher out of a patent granted to the company’s founder and CTO, Kenneth Gall, in June.
